Method Description

Purified beta-2 glycoprotein (B2GPI) antigen is bound to the wells of a polystyrene microwell plate under conditions that will preserve the antigen in its native state. Prediluted controls and diluted patient sera are added to separate wells, allowing any B2GPI IgM or IgG antibodies present to bind to the immobilized antigen. Unbound sample is washed away, and an enzyme-labeled antihuman IgM or IgG conjugate is added to each well. A second incubation allows the enzyme-labeled antihuman IgM or IgG to bind to any patient antibodies that have attached to the microwells. After washing away any unbound enzyme-labeled antihuman IgM or IgG, the remaining enzyme activity is measured by adding a chromogenic substrate and measuring the intensity of the color that develops. The assay can be evaluated spectrophotometrically by measuring and comparing the color intensity that develops in the patient wells with that of a 5-point calibration curve. Semiquantitative results are reported in standard IgM and IgG anti-B2GPI units (SMU and SGU, respectively).(Package inserts: QUANTA Lite beta 2 GP1 IgM ELISA. Inova Diagnostics; Revision 16, 09/2018; QUANTA Lite beta 2 GP1 IgG ELISA. Inova Diagnostics; Revision 19, 07/2020)